Florida Cancer Specialists - Sarasota
Florida Cancer Specialists - Sarasota
Sarasota, Florida, United States19 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NCI COVID-19 in Cancer Patients, NCCAPS Study | COVID-19, Coronaviridae Infections, Infections, Neoplasm Metastasis, Neoplastic Processes, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-10-07 | NCT04387656 | |
| Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-06 | NCT04214262 | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Adnexal Diseases, Carcinoma, Endometrioid, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, carcinosarcoma, endocrine system disorder, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium adenocarcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, mixed neoplasm, neoplasm, ovarian cancer, ovarian disorder, sarcoma | Active, not recruiting | Phase 2 | 2026-10-01 | NCT03660826 | |
| Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2026-09-30 | NCT03348631 | |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 1 | 2026-09-10 | NCT05557045 | |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Solid Tumor, Adult | Active, not recruiting | Phase 1 | 2026-09-02 | NCT06507306 | |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-02 | NCT05879926 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-08-28 | NCT04449874 | |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder transitional cell carcinoma, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-28 | NCT03775265 | |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Adnexal Diseases, Brain Tumor, Primary, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Stomatognathic Diseases, T-cell non-Hodgkin lymphoma, Thoracic Neoplasms, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, anaplastic large cell lymphoma, benign urinary system neoplasm, brain disorder, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, central nervous system cancer, central nervous system disorder, cholangiocarcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, mouth disorder, neoplasm, nervous system disorder, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, papillary adenocarcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor, urinary system disorder | Active, not recruiting | Phase 2 | 2026-08-25 | NCT02568267 | |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, carcinoma in situ of hypopharynx, carcinoma in situ of nasopharynx, epithelial neoplasm, head and neck squamous cell carcinoma, hypopharynx squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, laryngeal squamous cell carcinoma, mouth disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, nasopharyngeal squamous cell carcinoma, neoplasm, oropharynx squamous cell carcinoma, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, stomatitis | Recruiting | Phase 2 | 2026-08-17 | NCT06532279 | |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder | Recruiting | Not applicable | 2026-08-07 | NCT04251052 | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, skin disorder, skin neoplasm, squamous cell carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 | 2026-08-06 | NCT05581004 | |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, sarcoma, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-31 | NCT03914612 | |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-04-27 | NCT05705401 | |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, pulmonary large cell neuroendocrine carcinoma, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 1 | 2026-04-24 | NCT06736418 | |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-23 | NCT04852887 | |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Solid Tumor Malignancies | Recruiting | Phase 1 | 2026-03-03 | NCT06994806 | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 1 | 2026-02-27 | NCT05907304 |